Next-Generation Cancer Immunotherapy Targeting Glypican-3

Next-Generation Cancer Immunotherapy Targeting Glypican-3

Glypican-3 (GPC3), a 65 kD protein consisting of 580 amino acids, is a heparan sulfate proteoglycan bound to the cell membrane by glycosylphosphatidylinositol. This protein is expressed in the liver and the kidney of healthy fetuses but is hardly expressed in adults, except in the placenta. Contrari...

Full description

Bibliographic Details
Main Authors: Yasuhiro Shimizu, Toshihiro Suzuki, Toshiaki Yoshikawa, Itaru Endo, Tetsuya Nakatsura
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-04-01
Series:Frontiers in Oncology
Subjects:
glypican-3 (GPC3)
cancer antigen
cancer immunotherapy
cancer vaccine
cytotoxic T cell
TCR-engineered T cell therapy
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00248/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00248/full

Similar Items